Plain-English translation of NCT05337189 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Bladder Cancer research guide โThis trial is testing a new urine-based test called the Human Multigene Methylation Detection Kit that looks for specific genetic markers in your urine that may indicate bladder cancer. The researchers want to see how well this simple urine test works compared to standard bladder cancer diagnostic methods like imaging, cystoscopy (a camera exam of the bladder), and tissue biopsies. If successful, this could offer patients a non-invasive way to screen for or help diagnose bladder cancer.
Bladder cancer is often diagnosed late because current screening methods can be uncomfortable or invasive. This trial aims to develop a simpler, less invasive urine test that could catch bladder cancer earlier or rule it out more easily in people with symptoms or risk factors.
You would provide a urine sample at the study site, which will be tested using the new genetic detection kit. You would also undergo standard diagnostic testing (such as imaging, a cystoscopy exam, or a tissue biopsy) to confirm whether or not you have bladder cancer. The researchers will compare the results of the new urine test with the standard diagnostic results to see how accurate it is. The study is being conducted at multiple centers in China and is currently recruiting participants.
AI-generated summary from trial data ยท Jun 10, 2026 ยท Not medical advice
China
Sponsor
Creative Biosciences (Guangzhou) Co., Ltd.
Collaborators
Guangzhou Xiangkang Medical Research Co., Ltd.
Enrollment target
~482 participants
Started
March 2022
Primary completion
April 2025
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Xianshu Wang, PhD
Peking University Cancer Hospital & Institute